Business
CEO turned informant: How the FDA built a case against executives promising cheap medications
CRAYON summary
CNBC reports that the FDA brought a criminal case against an alternative funding program whose executives promised cheap medications. The outlet calls the case unprecedented. Citing a court record, CNBC says the case hinged on the cooperation of a CEO at a peer company who acted as an informant.
Based on CNBC's report - only one outlet has covered this so far. Read the original.▲ Sign in to vote stories up
Coverage 1 source · 1 report
Chronological.
-
CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
Discussion 0 comments